Background
==========

Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesion kinase (FAK) non-receptor tyrosine kinase family and has limited tissue expression, mainly in hematopoietic and neuronal tissues \[[@b1-medscimonit-24-8172],[@b2-medscimonit-24-8172]\]. Pyk2 is also known as related adhesion focal tyrosine kinase (RAFTK), cell adhesion kinase β (CAKβ), and calcium-dependent tyrosine kinase (CADTK), and it can be activated by multiple growth factors (GFs), neuropeptides, cytokines, hormones, and chemokines \[[@b2-medscimonit-24-8172]--[@b11-medscimonit-24-8172]\]. Pyk2 has been implicated in different signal transduction cascades and plays a critical role in controlling cell adhesion, proliferation, migration, and invasion \[[@b12-medscimonit-24-8172],[@b13-medscimonit-24-8172]\]. In recent years, the role that Pyk2 plays in tumor progression has attracted serious attention. Pyk2 has the three-domain organization that is associated with tumor progression ([Figure 1](#f1-medscimonit-24-8172){ref-type="fig"}), including NH~2~-terminal FERM domain, centrally located kinase domain, and C-terminal focal adhesion targeting (FAT) domain \[[@b14-medscimonit-24-8172]\]. The NH~2~-terminal FERM domain plays a central role in the regulation of Pyk2 kinase activity and receptor association \[[@b15-medscimonit-24-8172],[@b16-medscimonit-24-8172]\]. Pyk2 FERM domain is composed of 3 structural modules, designated F1, F2, and F3 \[[@b17-medscimonit-24-8172]\]. F3 module of Pyk2 FERM domain controls tumor cell migration via regulating Pyk2 phosphorylation \[[@b16-medscimonit-24-8172],[@b18-medscimonit-24-8172]--[@b20-medscimonit-24-8172]\]. Kinase activity of Pyk2 is generally initiated by autophosphorylation of the tyrosine Y402 situated in the FERM-kinase linker \[[@b21-medscimonit-24-8172]\]. The phosphorylation sites Tyr402, Tyr579, and Tyr580 are also reported to take part in regulating the growth of tumor cells \[[@b22-medscimonit-24-8172]--[@b24-medscimonit-24-8172]\]. Pyk2 has the centrally located kinase domain, which may be of potential use in the design of selective kinase inhibitors for targeting cancers \[[@b25-medscimonit-24-8172],[@b26-medscimonit-24-8172]\]. The C-terminal FAT domain of Pyk2, which has autophosphorylation site Tyr881, is associated with the mitogen-activated protein kinase (MAPK) signaling pathway and cancer development \[[@b26-medscimonit-24-8172],[@b27-medscimonit-24-8172]\]. In addition, Pyk2 has 3 proline-rich sequences that regulate interactions with proteins. Among them, the C-terminal domain contains 2 proline-rich motifs that control proteins possessing Src homology 3 (SH3) domains \[[@b28-medscimonit-24-8172]\].

Overexpression of Pyk2 is found in many kinds of malignant tumors and it promotes tumor progression. Pyk2 has traditionally been considered as one of the most promising therapeutic targets for cancer treatment. However, a few studies have found a suppressive role of Pyk2 in tumor growth and metastasis. These paradoxical findings need to be elucidated, as they may be relevant to the adverse effects of Pyk2-targeting treatment and failure of Pyk2-related anti-cancer treatments fail to achieve optimal outcomes. In this review, we provide a new overview of the roles of Pyk2 in multiple cancers. We focus on the interconnectivity between Pyk2 and its downstream targets involved in the biological processes of tumorigenesis and tumor development, as well as furthering the identification of potential targets for cancer therapy and contributing to Pyk2-related anti-cancer drug discovery research.

Aberrant Expression and the Roles of Pyk2 in Different Cancers
==============================================================

Pyk2 is aberrantly expressed in breast cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, intestinal cancer, multiple myeloma, ovarian cancer, prostate cancer, glioma, squamous cell carcinoma of the head and neck (SCCHN), bladder cancer, and neuroblastoma, compared to normal tissues ([Table 1](#t1-medscimonit-24-8172){ref-type="table"}). In most cancers, functional studies have shown that aberrant expression of Pyk2 promotes cancer cell proliferation, migration, invasion, metastasis, and chemo-resistance. However, Pyk2 shows its suppressive role in a few tumors.

Breast Cancer
=============

Pyk2 is highly expressed and significantly associated with lymph-node metastasis (LNM) in triple-negative breast cancer (TNBC). High levels of Pyk2 and epidermal growth factor receptor (EGFR) contribute to poor prognosis of TNBC patients. Pyk2 depletion can promote proteasomal degradation of tumor-related human epidermal growth factor receptor 3 (HER3), while the Pyk2-NDRG1 (N-myc downstream regulated 1 gene)-NEDD4 (neural precursor cell-expressed developmentally downregulated gene 4) axis is identified as a key regulator of HER3 degradation. Concomitant targeting of EGFR and Pyk2 is proved to inhibit complementary key growth and survival pathways of breast cancer cells, which are mediated by Akt, S6 kinase (S6K), signal transducer and activator of transcription 3 (STAT3), and extracellular signal-regulated protein kinase 1/2 (ERK1/2) activation, and it is a more effective way to overcome HER3-associated resistance to EGFR antagonists in TNBC \[[@b29-medscimonit-24-8172]\]. Pyk2 acts as a crossroads of multiple signaling pathways and promotes breast cancer progression. Carcinogen benzo\[a\]pyrene diol epoxide (BPDE) increases intracellular Ca^2+^ concentration and activates the Pyk2/EGFR/Akt signaling pathway, which plays an important role in inhibiting apoptosis of breast cancer cells \[[@b30-medscimonit-24-8172]\]. Compensatory Pyk2 expression after FAK deletion in mammary cancer stem cells (MaCSCs) promotes breast cancer tumorigenicity and metastasis via activation of the PI3K/Akt signaling pathway \[[@b31-medscimonit-24-8172]\]. Glutathione S-transferase omega 1 (GSTO1)-induced cytosolic calcium increase activates the Pyk2/Src/STAT3 signaling pathway and leads to breast cancer stem cell (BCSC) enrichment, which is essential for breast cancer recurrence and metastasis \[[@b32-medscimonit-24-8172]\]. Pyk2 promotes ErbB-induced cell proliferation and tumor growth, in part via activating the MAPK signaling pathway \[[@b33-medscimonit-24-8172]\]. Pyk2 was found to promote migration and invasion of breast cancer cells. Pyk2 is phosphorylated by heregulin (HRG) stimulation and participates in the formation of a multiprotein complex correlated with p190 RhoGAP (p190), RasGAP, ErbB-2, and Src, and plays a key role in activation of the MAPK signaling pathway and breast cancer cell invasion \[[@b34-medscimonit-24-8172]\]. Pyk2 is associated with cell adhesion and motility in human breast cancer \[[@b35-medscimonit-24-8172]\]. Pyk2 promotes breast cancer cell invasion via enhancing matrix metalloproteinase (MMP) secretion, extracellular matrix (ECM) degradation, and invadopodium-mediated functions. Pyk2 colocalizes with cortactin to invadopodia of breast cancer cells, where it regulates epidermal growth factor(EGF)-induced cortactin phosphorylation through Src-mediated Abl-related gene (Arg) activation, resulting in actin polymerization and tumor cell invasion \[[@b36-medscimonit-24-8172]\]. EGF activates Pyk2 expression, which can promote EMT, migration, invasion, and metastasis of breast cancer cells through modulating the functions of MMP-10, β-Catenin, fibronectin, vimentin, E-cadherin, ZO-1, Twist-1,2, CD44, Snail-1,2 and Zeb-1,2. With EGF stimulation, Pyk2 affects STAT3 phosphorylation and the protein and mRNA levels of c-Met, c-Met enhances the phosphorylation of Pyk2 and STAT3 and also STAT3 regulates Pyk2 transcription and c-Met expression in human breast carcinoma, forming a positive feedback in the PYK2-STAT3-c-Met axis that contributes to cancer metastasis and prolongs EMT-associated signals in breast cancer \[[@b12-medscimonit-24-8172]\]. Pyk2 N-terminal domain interacting receptor 1 (Nir1) promotes epithelial-mesenchymal transition (EMT) and metastasis of human breast cancer cells by binding to (C-C motif) ligand 18 (CCL18) via activating the Pyk2/Akt/GSK3β/Snail signaling pathway \[[@b37-medscimonit-24-8172]\]. Transforming growth factor-β (TGF-β) upregulates Pyk2 expression, which induces diminished E-cadherin and stabilized β1 integrin, facilitates epithelial-mesenchymal transition, and leads to breast cancer cell metastasis, through Smad4- and Src-dependent pathways \[[@b38-medscimonit-24-8172]\]. Csk homologous kinase (CHK) is proved to regulate the activation of HRG- and Pyk2-mediated intracellular signaling and breast cancer cell migration \[[@b39-medscimonit-24-8172]\]. Inhibition of tyrosine phosphorylation of Pyk2 and paxillin can suppress breast cancer cell migration, which is induced by the deficiency of tumor suppressor protein tyrosine phosphatase non-receptor type 12(PTPN12) \[[@b40-medscimonit-24-8172]\]. Pyk2 plays a key role in chemokine CCL18-induced adhesion, migration, and invasion of breast cancer cells through phosphorylating the GTPase-activating protein AMAP1 \[[@b41-medscimonit-24-8172]\]. After binding to its functional G protein-coupled receptor PITPNM3, CCL18 in turn activates Pyk2 and Src, which are required for integrin α/β1 clustering-dependent cell adherence and cell migration and invasion in breast cancer. Activated Pyk2 translocates from the cytoplasm to the membrane and forms a stable complex with PITPNM3, which activates the intracellular CCL18-induced signaling pathway \[[@b42-medscimonit-24-8172]\]. C-X-C motif chemokine 12 (CXCL12) can induce the tyrosine phosphorylation of Pyk2 at residues 402 and 579/580, while inhibition of Pyk2 particularly precludes CXCL12-induced cell migration and invasion in breast cancer \[[@b43-medscimonit-24-8172]\]. The Src/FAK/Pyk2/p130 Cas (crk-associated substrate) pathway is proved to be an effective pathway to control migration and invasion of breast cancer cells \[[@b44-medscimonit-24-8172]\]. Additionally, inhibition of Pyk2 can arrest estrogen-dependent breast tumor angiogenesis \[[@b45-medscimonit-24-8172]\]. Alpha-naphthoflavone (ANF) significantly promotes the sensitivity of breast cancer cells to the chemopreventive agent doxorubicin and abrogates doxorubicin resistance via inhibiting phospho-Pyk2 (Y579/580), phospho-FAK (Y397) and EGF-induced Akt activation \[[@b22-medscimonit-24-8172]\]. Pyk2 acts as an oncogene and enhances tumor progression in breast cancer.

Liver Cancer
============

Overexpression of Pyk2 is found in 59% of hepatocellular carcinoma (HCC) patients. Pyk2 expression is positively correlated with HCC invasiveness, metastasis, recurrence, and poor survival of patients, as well as the gene expression of ezrin and fibronectin \[[@b46-medscimonit-24-8172]\]. Pyk2 activation leads to cisplatin resistance of hepatocellular carcinoma (HCC) cells through increasing Akt phosphorylation, upregulating drug-resistant genes, and inhibiting cell necrosis and apoptosis \[[@b47-medscimonit-24-8172]\]. The phosphoinositide 3-kinase (PI3K)/Akt pathway is associated with Pyk2-mediated vascular endothelial growth factor (VEGF) expression, which promotes tumor angiogenesis during HCC progression \[[@b48-medscimonit-24-8172]\]. Additionally, Pyk2 promotes HCC cell proliferation and invasiveness by activating the c-Src and ERK/MAPK signaling pathways, which can be arrested by overexpression of the Pyk2-related non-kinase (PRNK). The Pyk2 phosphorylated form pY402 plays a role in upregulating actin stress fiber polymerization and HCC cell motility \[[@b49-medscimonit-24-8172]\]. Pyk2 plays a critical role in liver cancer progression. Overexpression of microRNA 517a (miR-517a) and miR-517c directly decreases Pyk2 expression by specific binding to the 3′UTR region (3870--4152) of Pyk2 and cleaving its mRNA. Subsequently, degradation of Pyk2 mRNA inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells \[[@b13-medscimonit-24-8172]\]. After activating Rho small GTPases Rac1 and RhoA, Pyk2 enhances the formation of membrane ruffles and HCC cell motility. Pyk2 regulates EMT and promotes HCC progression through downregulating epithelial gene E-cadherin and cytokeratin and upregulating mesenchymal gene hydrogen peroxide inducible clone-5 (Hic-5), STAT5b, Twist, N-cadherin and fibronectin \[[@b50-medscimonit-24-8172]\]. miR-23b can inhibit EMT of HCC by targeting the 3′UTR region of Pyk2 \[[@b51-medscimonit-24-8172]\]. Inhibition of receptor membrane-associated phosphatidylinositol transfer protein 3 (PITPNM3) arrests the invasiveness and metastasis of HCC cells through suppressing the activation of Pyk2, which plays a role in supporting the clustering of integrin in HCC \[[@b52-medscimonit-24-8172]\]. Cytosolic calcium and cytosolic calcium-dependent Pyk2-Src signaling pathway are essential for HBx-regulated HBV DNA replication and reverse transcription, which can support liver cancer development \[[@b53-medscimonit-24-8172]\]. In cholangiocarcinoma (CC), overexpressed Eph receptor 2 (EphA2) phosphorylates Akt at T308 and Pyk2 at Y402, and at the same time EphA2 activates mammalian target of rapamycin complex1 (mTORC1). The EphA2/Akt/mTORC1 pathway mainly regulates cell proliferation, while the EphA2/Pyk2/c-Src/ERK pathway plays a major role in modulating CC metastatic ability. Moreover, these 2 pathways also appear to strongly influence each other in CC development \[[@b23-medscimonit-24-8172]\].

Lung Cancer
===========

Pyk2 mRNA, total protein, and Pyk2 phosphorylated form pY881 (Pyk2\[pY881\]) are found to be higher in lung cancer tissues than in normal lung tissues. Pyk2 is proved to be an independent prognostic factor for non-small-cell lung cancer (NSCLC) patients, and patients with high Pyk2 and Pyk2 \[pY881\] expression show poorer overall survival. Pyk2 is associated with the expression of cancer stem cell markers ALDH1a1, ABCG2, and Bmi-1 \[[@b26-medscimonit-24-8172]\]. Pyk2 is significantly correlated with advanced stage of NSCLC and lymph-node metastasis. Phosphorylation of Pyk2 can promote the activity of ERK1/2 and result in the progression of NSCLC \[[@b54-medscimonit-24-8172]\]. The overexpressed Pyk2 in NSCLC is negatively correlated with suppressor cytokine signaling 3 (SOCS3), which can inhibit cell proliferation and invasion in NSCLC \[[@b55-medscimonit-24-8172]\]. SOCS3 binds to Pyk2 via its Src homology 2 (SH2) and the kinase inhibitory region (KIR) domains, and decreases cell migration of NSCLC through inhibiting Pyk2-associated ERK1/2 activity \[[@b56-medscimonit-24-8172]\]. Pyk2 acts as a critical downstream effecter in the Src-mediated human lung adenocarcinoma cell survival pathway \[[@b57-medscimonit-24-8172]\]. Pyk2 and p-Pyk2 are increased significantly in NSCLC apoptotic cells \[[@b58-medscimonit-24-8172]\]. In small cell lung cancer (SCLC), neuropeptides increase calcium (Ca^2+^) concentration, phosphorylation of highly expressed Pyk2, Src kinase activation, and Pyk2/Src association, which contribute to the GTP-loading of Ras and ERK activation, leading to the promotion of cancer cell proliferation \[[@b5-medscimonit-24-8172]\].

Leukemia
========

Pyk2 is abundantly expressed in hematopoietic cells. In acute promyelocytic leukemia (APL), N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) induces tyrosine phosphorylation of Pyk2 and β2 integrin activation. β2 integrin induces cell attachment on fibrinogen-coated dishes, while cell attachment to fibrinogen causes the enhanced Pyk2 phosphorylation. Thus, Pyk2 participates in functional activation of APL cells \[[@b59-medscimonit-24-8172]\]. Pyk2 plays a critical role in the differentiation of promyelomonocytic leukemic cells, which is induced by stromal cell-derived factor-1 (SDF-1/CXCL12) and all-trans-retinoic acid (ATRA), accompanied by activation of the transcription factor CCAAT enhancer-binding protein (C/EBP) β \[[@b60-medscimonit-24-8172]\]. After C/EBPβ binds to and transactivates the Pyk2 promoter, the expression of Pyk2 is upregulated during phorbol 12-mystate 13-acetate (PMA)-induced monocytic differentiation of acute promyelocytic leukemia cells through the MAPK/ERK pathway \[[@b61-medscimonit-24-8172]\]. PMA treatment upregulates the expression of Pyk2, while Pyk2 phosphorylation increases upon adherence of human leukemic cell to fibronectin and to stromal cells \[[@b62-medscimonit-24-8172]\]. In acute promyelocytic leukemia, ATRA treatment upregulates Pyk2 mRNA, protein, and phosphorylation levels and enhances APL cell adhesion, migration, and invasion capabilities. Targeting Pyk2 can inhibit APL cell adhesion and migration, and its interaction with paxillin and vinculin reduces the extramedullary relapse (EMR) in APL \[[@b63-medscimonit-24-8172]\]. In the same way, Pyk2 inhibition reduces EMR of chronic myeloid leukemia (CML) subsequent to imatinib treatment \[[@b64-medscimonit-24-8172]\]. Pyk2 plays a key role in CML pathogenesis, which is caused by the p210 BCR/ABL oncoprotein \[[@b65-medscimonit-24-8172]\]. FAK increases expression of Frizzled-4 and phosphorylates Pyk2 on its Y579 residue to enable the required association of Pyk2 with the Wnt5a/Frizzled-4/Low-density lipoprotein receptor-related proteins 5 (LRP5) endocytosis complex and β-catenin activation, thereby maintaining the growth of primitive acute myeloid leukemia (AML) cells \[[@b66-medscimonit-24-8172]\]. Pyk2 regulates AML cell adhesion and enhances AML progression through cross-talking with FMS-like receptor tyrosine kinase 3 (FLT3) and β1 integrin \[[@b67-medscimonit-24-8172]\]. Ethoxy fagaronine has anti-adhesive potential and inhibits leukemic cell survival via reducing Pyk2 phosphorylation on Tyr 579, impairing β1 integrin clustering and inhibiting phosphatidylinositol 3-kinase (PI 3-kinase) activity \[[@b24-medscimonit-24-8172]\]. Pyk2 acts as an oncogene and participates in maintaining leukemia development.

Pancreatic Cancer
=================

In pancreatic ductal adenocarcinoma (PDA), Pyk2 expression is easily observed. The cell migration of PDA cells and cells that comprise the tumor microenvironment is implicated in the catalytic activity of Pyk2 \[[@b68-medscimonit-24-8172]\]. Discoidin domain receptor 1 (DDR1), which plays a key role in protumorigenic signaling, can be stimulated by collagen through activating Pyk2 and pseudopodium-enriched atypical kinase 1 (PEAK1) in pancreatic cancer cells \[[@b69-medscimonit-24-8172]\]. A study shows that Pyk2 acts downstream of DDR1 and is phosphorylated in response to collagen I. DDR1 is in a complex with p130 Crk-associated substrate (p130CAS), and this association is induced by collagen I. Rap1 guanosine triphosphatase (Rap1 GTPase), MAPK kinase (MKK)7, and mixed lineage kinases (MLK)3 are required for the response to collagen I, which leads to the activation of c-Jun N-terminal kinase 1 (JNK1). c-Jun plays a key role in the process by which activated JNK1 upregulates the expression of N-cadherin, which can promote human pancreatic cancer cells growth, invasion, and metastasis \[[@b70-medscimonit-24-8172]\]. DDR1 and Pyk2 are necessary for pancreatic cancer development. Isoform b of DDR1 regulates collagen I-induced N-cadherin upregulation, which can promote pancreatic cancer progression, and Src homology and collagen homology 1(Shc1) play a critical role in this process by coupling to Pyk2 and DDR1 \[[@b71-medscimonit-24-8172]\].

Intestinal cancer
=================

Pyk2 is overexpressed in intestinal cancer. *In vitro* and *in vivo*, elevated Pyk2 is found to function redundantly in regulation of the Wnt/β-catenin pathway by phosphorylating GSK3β^Y216^, which can induce the recruitment of β-transducin repeats-containing proteins (β-TrCP) and reinforce intestinal tumorigenesis \[[@b72-medscimonit-24-8172]\].

Multiple Myeloma
================

Patients with multiple myeloma (MM) are proved to present with overexpression of Pyk2 compared with healthy individuals. *In vitro* and *in vivo*, Pyk2 plays a tumor-promoting role in MM cell-cycle progression, adhesion ability, and cell proliferation by activating Wnt/β-catenin signaling. Pyk2 protects β-catenin from GSK3β-induced degradation, while inhibition of Pyk2 results in destabilizing β-catenin and downregulation of c-Myc and Cyclin D1. Moreover, inhibition of Pyk2 leads to decreased p-Akt, which indicates that Pyk2 may also regulate β-catenin through modulating the phosphatidylinositol 3-kinase/Akt/GSK3β pathway \[[@b73-medscimonit-24-8172]\]. The iron chelator deferasirox (DFX) can inhibit Pyk2/β-catenin signaling and induce MM cell apoptosis, following a decrease in reactive oxygen species (ROS) production \[[@b74-medscimonit-24-8172]\]. Pyk2 is a critical mediator of the multiple myeloma cell survival pathway. Pyk2 shows a more malignant phenotype via enhancing JAK1 (janus kinase 1)/STAT3 signaling linking β1 integrin-mediated adhesion and gp130 (interleukin-6 beta receptor). DEP domain-containing mTOR-interacting protein (DEPTOR), a negative regulator of the mTOR pathway, is a downstream effector of Pyk2 and STAT3 signaling under fibronectin-mediated adhesion and interleukin-6 (IL-6) stimulation, which regulate MM cell growth and proliferation \[[@b75-medscimonit-24-8172]\]. IL-6 can inhibit the activation of Pyk2 and the apoptosis of MM cells triggered by dexamethasone (Dex) \[[@b76-medscimonit-24-8172]\]. Protein tyrosine phosphatase SHP2 is proved to mediate this protective effect of IL-6. In Dex-treated MM cells, IL-6 induces selective activation of SHP2, and activated SHP2 interacts with Pyk2 through the phosphorylation site Tyr906 in the C-terminal domain of Pyk2, leading to the dephosphorylation of Pyk2 and the inhibition of MM cell apoptosis \[[@b77-medscimonit-24-8172]\].

Ovarian Cancer
==============

Phosphorylated Pyk2 was detected in 82.1% of high-grade serous ovarian cancer (OC) tissues. Women with phosphorylated Pyk2-positive ovarian cancer had a shorter progression-free survival and overall survival than women with phosphorylated Pyk2-negative ovarian cancer. CCL18 and OC ascites, which has CCL18 in it, elicit Pyk2 activation in OC cells, while activated Pyk2 plays a significant role in ovarian cancer cell migration and ovarian cancer progression \[[@b7-medscimonit-24-8172]\]. Additionally, ovarian cancer cells are able to secrete IL-6, which induces the phosphorylation of Pyk2, leading to chemo-resistance \[[@b78-medscimonit-24-8172]\]. Exogenous EGF induces telomerase activity and promotes cancer cell survival through activating the Pyk2/ERK 1/2 pathway and targeting Spl and c-Myc binding sites within the core region of the human telomerase reverse transcriptase gene (hTERT) promoter in malignant ovarian epithelial cells \[[@b79-medscimonit-24-8172]\]. In murine ID8 ovarian carcinoma cells, Pyk2 knockdown induces elevated p53, which is regulated by Pyk2 FERM domain, inhibits ID8 cell proliferation, and leads to G 1 cell cycle arrest \[[@b80-medscimonit-24-8172]\]. Pyk2 acts as an oncogene in ovarian cancer.

Prostate Cancer
===============

In prostate cancer, although there is no significant correlation between Pyk2 expression and tumor staging, overexpression of Pyk2 was found in 32.4% of tumor samples. Pyk2 is significantly correlated with androgen receptor (AR) function and prostate cancer cell growth via activating ribosomal S6K1 \[[@b81-medscimonit-24-8172]\]. Pyk2 takes part in numerous signaling pathways and promotes prostate cancer progression. Pyk2 plays an important role in controlling the state of cell differentiation and promotes the proliferation of prostatic cancer cells via activating the MAPK signaling pathway \[[@b82-medscimonit-24-8172]\]. The elevated ErbB-2, through the activation of Pyk2, increases ERK/MAPK activity and enhances the adhesive ability and metastasis of human prostate cancer (PCa) cells \[[@b83-medscimonit-24-8172]\]. RhoC, one of the Ras-homologous family genes, enhances tumor distant metastasis by sequentially phosphorylating Pyk2, FAK, MAPK, and Akt and increases the invasiveness of prostate tumor cells, which is followed by overexpression of MMP2 and MMP9 \[[@b84-medscimonit-24-8172]\]. Leupaxin promotes the migration of prostate cancer cells via activating Pyk2, c-Src, and Rho GTPase, which can be inhibited by the cytoplasmic protein tyrosine phosphatase-proline-, glutamate-, serine-, and threonine-rich sequence (PTP-PEST) \[[@b85-medscimonit-24-8172]\]. However, a few studies showed that the expression of Pyk2 was inversely associated with prostate malignancy. Pyk2 can be found in nearly all normal prostate tissues, while high-grade prostate tumors show complete loss of Pyk2 \[[@b86-medscimonit-24-8172]\]. The full-length androgen receptor-associated protein ARA55, a nuclear receptor coactivator, enhances the androgen receptor (AR) function in a ligand-dependent manner and plays a negative role in the proliferation and aggression of prostate cancers \[[@b87-medscimonit-24-8172]--[@b90-medscimonit-24-8172]\]. Phospho-Pyk2 directly induces ARA55 phosphorylation at tyrosine 43, impairs the coactivator activity of ARA55 to reduce its interaction with AR, and controls prostate tumor progression \[[@b91-medscimonit-24-8172]\]. Pyk2 is involved in olfactory receptor signaling and conveys the anti-proliferative effect in androgen-sensitive prostate cancer cells. Prostate-specific G-protein-coupled receptor 1 (PSGR1), an olfactory receptor, is activated by β-ionone, which induces an upregulation in cytosolic Ca^2+^ and an increase of Pyk2 phosphorylation at Ser375. Subsequently, phospho-Pyk2 activates the p38 MAPK signaling pathway, leads to dephosphorylation in tumor-suppressor protein NDRG1 at Ser330, and plays a key role in inhibiting androgen-dependent prostate tumor progression \[[@b92-medscimonit-24-8172]\]. To the best of our knowledge, most of the prostate tumor types in which Pyk2 functions as a suppressor in the tumor are androgen-dependent. A study showed that androgen-dependent prostate cancer cells have a surfeit of Pyk2, while androgen-independent prostate cancer cells show a shortage of Pyk2 \[[@b93-medscimonit-24-8172]\]. The decrease of steroid receptor function is followed by the inhibition of Pyk2 expression. In high-grade prostate cancer, the activity of steroid receptors is destroyed and Pyk2 is found to be totally absent \[[@b86-medscimonit-24-8172]\]. Pyk2 and steroid receptors cooperate in inhibiting prostate tumor progression through different pathways ([Figure 2](#f2-medscimonit-24-8172){ref-type="fig"}).

Glioma
======

Glioma includes astrocytomas, medulloblastomas, and oligodendroglioma. Pyk2 shows a high expression in glioma *in vitro* and *in vivo*. Overexpression of Pyk2 is positively associated with malignant grade of astrocytic tumors, and Pyk2 is found to be overexpressed in 77.4% of astrocytomas. Additionally, Pyk2 overexpression occurs in 84.1% of glioblastoma, which are the most malignant astrocytoma \[[@b94-medscimonit-24-8172]\]. Upregulated Pyk2 significantly increases glioma cell migration \[[@b95-medscimonit-24-8172]\]. Soluble factors, released from microglia, enhance glioma cell migration by increasing the phosphorylation levels of Pyk2 at Tyr 579/580 \[[@b96-medscimonit-24-8172]\]. Glioma cell migration requires autophosphorylation of Pyk2 Y402 and the N-terminal FERM domain of Pyk2 \[[@b97-medscimonit-24-8172]\]. Orai1, the key component mediating Store-operated Ca^2+^ entry (SOCE), controls glioma cell focal adhesion turnover and epithelial-to-mesenchymal (−like) transition (EMT-like) via the Pyk2 pathway \[[@b98-medscimonit-24-8172]\]. MiR-23b significantly inhibits glioma cell migration and invasion via targeting the 3′ UTR of Pyk2 \[[@b99-medscimonit-24-8172]\]. Knockdown of Pyk2 inhibits glioma distant metastasis and extends survival duration of orthotopic glioma xenografts \[[@b100-medscimonit-24-8172]\]. Focal adhesion kinase family interacting protein (FIP200) downregulation enhances the autophosphorylation levels of Pyk2 at Tyr 402, which plays a role in inducing apoptosis of glioblastoma cells \[[@b101-medscimonit-24-8172]\].

Pyk2 lies downstream of the tumor necrosis factor receptor superfamily expressed on the mouse embryo (TROY), and depletion of Pyk2 suppresses TROY-induced Rac1 activity, followed by inhibition of TROY-mediated glioma cell migration \[[@b102-medscimonit-24-8172],[@b103-medscimonit-24-8172]\]. In C6 glioma cells, blockage of Ca^2+^-permeable nonselective cation channels and inhibition of PI3K attenuate endothelin-1-induced Pyk2 phosphorylation \[[@b104-medscimonit-24-8172]\]. Glioma cell migration and invasion, which is induced by hypoxia, can be decreased by melatonin via inhibiting ROS-αv-β3 integrin-FAK/Pyk2 signaling pathways \[[@b105-medscimonit-24-8172]\]. Under the influence of a novel heregulin/HER3-stimulated signaling pathway, phosphorylated Pyk2 activates the MAPK pathway, which plays a critical role in regulating invasiveness of glioma cells \[[@b106-medscimonit-24-8172]\]. c-Met enhances Pyk2 phosphorylation, while Pyk2 mediates the effects of c-Met on the proliferation, migration, and invasion of medulloblastoma cells \[[@b107-medscimonit-24-8172]\]. VEGF plays a critical role in tumor development. Although anti-VEGF treatment increases Pyk2 phosphorylation, which promotes glioma cell migration and invasion, anti-VEGF treatment plus Pyk2 inhibitor PPI cannot prolong median survival time of rats with intracranial xenograft when compared with anti-VEGF treatment alone \[[@b108-medscimonit-24-8172]\]. In summary, Pyk2 acts as an oncogene and takes part in many different signaling pathways to promote glioma progression. The roles that Pyk2 play in the different tumor types of glioma are not always the same.

Squamous Cell Carcinoma of the Head and Neck
============================================

Pyk2 is highly upregulated in the squamous cell carcinoma of the head and neck (SCCHN) and metastatic lymph-node cells. Pyk2 inhibitor blunts the phosphorylation of STAT3 elicited by CCL19, which is critical for regulating EMT biology in fibrogenesis and cancer \[[@b109-medscimonit-24-8172]\]. Additionally, CCL19-induced Pyk2 phosphorylation and cofilin activation are arrested by small GTPase protein RhoA and Rho-associated kinase (ROCK) inhibitors, and this signal pathway is crucial in decreasing SCCHN cell chemotaxis and migration \[[@b110-medscimonit-24-8172]\]. Pyk2 is a critical modulator of cancer cell migration and invasion. E-cadherin and vimentin may act as downstream target molecules of chemokine receptor 7(CCR7)-Pyk2, and this signaling pathway may participate in the regulation of migration and invasion of squamous cell carcinoma of the head and neck \[[@b111-medscimonit-24-8172]\]. In squamous cell carcinoma of the head and neck, CCR7 upregulates the phosphorylation of Pyk2 and cofilin activation and enhances cervical lymph-node metastasis, followed by rearrangement of F-actin \[[@b110-medscimonit-24-8172]--[@b112-medscimonit-24-8172]\].

Bladder Cancer
==============

Pyk2 is overexpressed in various bladder cancer tissues and mainly locates in the nuclei of urothelial cancer tissue cells. As an oncogene in bladder cancer, Pyk2 serves as a diagnostic and possibly prognostic biomarker. Pyk2 is strongly activated by insulin-like growth factor I (IGF-I) in urothelial carcinoma cells, which is critical for IGF-IR-dependent invasion and can regulate IGF-I-dependent activation of the Akt and MAPK pathways by recruiting insulin receptor substrate-2 (IRS-2) and growth factor receptor-bound protein 2 (Grb2). Knockdown of Pyk2 inhibits IGF-I-dependent activation of ERK1/2 and ribosomal protein S6K, as well as urothelial carcinoma cell growth \[[@b113-medscimonit-24-8172]\]. Additionally, 2-Arylidenedihydroindole-3-ones decreases bladder tumor cell proliferation via inhibiting the expression of p-Stat5 and p-Pyk2 \[[@b114-medscimonit-24-8172]\].

Neuroblastoma
=============

The phosphorylation of Pyk2 can be induced by acrylamide, colchicine, and vincristine, while src-family selective tyrosine kinase inhibitor PP1 and compound-1 decrease the phosphorylation of Pyk2 in neuroblastoma cells. Compound-1 plays a role in rescuing colchicine-induced neuroblastoma cell death by inhibiting phosphorylation of Pyk2 ([Figure 3](#f3-medscimonit-24-8172){ref-type="fig"}). Pyk2 may act as a tumor suppressor in neuroblastoma progression \[[@b115-medscimonit-24-8172]\].

Other Cancers
=============

Pyk2 is found to be highly expressed in 34% of diffuse large B cell lymphoma (DLBCL) patients \[[@b116-medscimonit-24-8172]\]. In rat pheochromocytoma (PC12) cells, hypoxia induces a strong increase of Pyk2 phosphorylation in the presence of Ca^2+^. The phospho-Pyk2 then activates MAPK signaling pathways and promotes pheochromocytoma progression \[[@b117-medscimonit-24-8172]\]. Inhibition of Pyk2 decreases activation of the JNK signaling pathway, which is induced by ultraviolet light or sorbitol, and precludes the growth of PC12 cells \[[@b118-medscimonit-24-8172]\].

Conclusions
===========

Pyk2 is widely and highly expressed in human cancers. Numerous correlative studies describing enhanced expression of Pyk2 in human cancers provide strong evidence that Pyk2 serves key roles as oncogenic factors in most of cancers. Pyk2 acts as a supporter and facilities tumor cell proliferation, survival, migration, invasion, metastasis, and chemo-resistance. Overexpression of Pyk2 leads to poor prognosis and shortened survival in various cancers. However, the tumor-suppressive role of Pyk2 has been observed in androgen-dependent prostate cancer cells and neuroblastoma cells. In androgen-dependent prostate cancers, Pyk2 conveys the anti-proliferative effect and inhibits cancer progression. In neuroblastoma, the phosphorylation of Pyk2 results in neuroblastoma cell death. Additionally, activated Pyk2 is observed to induce the apoptosis of lung cancer cells, MM cells, and glioblastoma cells. Most of the prostate tumor types in which Pyk2 exerts suppressive functions in tumors are androgen-dependent. The decrease of steroid receptor function may lead to the inhibition of Pyk2 expression. In high-grade prostate cancer, the damaged steroid receptors are followed by absent of Pyk2. Pyk2 and AR may cooperate on inhibiting prostate cancer progression. Pyk2 has both tumor-driving and tumor-suppressive roles in cancers in a tissue-dependent manner. Different tumors originate from distinct cell types and grow in diverse environments, which may explain the various Pyk2 responses and contradictory functions of Pyk2 in distinct tumors. The possible adverse effects of promoting cancer progression should be fully considered before treating cancer with Pyk2 inhibitors.
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![Schematic model of Pyk2 functional domains correlated with tumor progression. Pyk2 contains an N-terminal FERM domain, a central kinase domain, and a C-terminal focal adhesion targeting (FAT) domain. The phosphorylation sites Tyr402, Tyr579, Tyr580, and Tyr881 also take part in regulating the growth of tumor cells. Additionally, Pyk2 includes 3 proline-rich regions located among the structure domains of Pyk2.](medscimonit-24-8172-g001){#f1-medscimonit-24-8172}

![Schematic model of the suppressive role of Pyk2 in prostate cancer progression. Black arrows indicate a promoting effect and red arrows indicate an inhibiting effect. The activation of Pyk2 inhibits cancer progression in androgen-dependent prostate cancer.](medscimonit-24-8172-g002){#f2-medscimonit-24-8172}

![Schematic model of the suppressor role of Pyk2 in neuroblastoma progression. Black arrows show the promoting effect and red arrows show the inhibiting effect. The activation of Pyk2 leads to neuroblastoma cell death. Regulation of Pyk2 phosphorylation can affect neuroblastoma progression.](medscimonit-24-8172-g003){#f3-medscimonit-24-8172}
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The expression and roles of Pyk2 in human cancers.

  Cancer type         Incidence                                                                                                                                                                                                                                                                              Expression in tissues   Downstream target sites of Pyk2 in cancer                                                                                                                                              Role of Pyk2 in cancer       Reference
  ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Breast cancer       79.3% (73/92) of breast cancer tissue samples is with high-to-moderate Pyk2 expression; 76% (41/54) of high-grade breast cancer tissue samples shows high Pyk2 expression; 92.8%(26/28) breast cancer tissue samples with positive lymph-node shows high-to-moderate Pyk2 expression   Overexpressed           p130 Cas; AMAP1; β1 integrin; c-Met; Twist-1,2; CD44; fibronectin; Zeb-1,2; Snail-1,2; ZO-1; MMP; EGFR; Arg; NDRG1; HER3; β-catenin; Src; Akt; S6K; vimentin; E-cadherin; STAT3; ERK   Oncogene                     \[[@b12-medscimonit-24-8172],[@b29-medscimonit-24-8172],[@b34-medscimonit-24-8172],[@b36-medscimonit-24-8172], [@b38-medscimonit-24-8172],[@b40-medscimonit-24-8172],[@b44-medscimonit-24-8172],[@b119-medscimonit-24-8172]\]
  Liver cancer        hepatocellular carcinoma (59% or 29/49)                                                                                                                                                                                                                                                Overexpressed           N-cadherin; Hic-5; cytokeratin; STAT5b; MEK1/2; fibronectin; Src; Akt; E-cadherin; ERK                                                                                                 Oncogene                     \[[@b13-medscimonit-24-8172],[@b23-medscimonit-24-8172],[@b46-medscimonit-24-8172], [@b51-medscimonit-24-8172],[@b53-medscimonit-24-8172]\]
  Lung cancer         97% (124/128) of NSCLC patient tissues express Pyk2, 54.7% (70/128) of NSCLC patient tissues highly express Pyk2. 92% (118/128) of NSCLC patient tissues express Pyk2\[pY881\], 60.2% (77/128) of NSCLC patient tissues highly express Pyk2 \[pY881\].                                 Overexpressed           Src; ALDH1a1; ABCG2; Bmi-1; ERK                                                                                                                                                        Oncogene                     \[[@b5-medscimonit-24-8172],[@b26-medscimonit-24-8172],[@b54-medscimonit-24-8172],[@b57-medscimonit-24-8172]\]
  Leukemia            Pyk2 is expressed in 81% (49/60) of AML                                                                                                                                                                                                                                                abundantly express      Unknown                                                                                                                                                                                Oncogene                     \[[@b67-medscimonit-24-8172]\]
  Pancreatic cancer   Unknown                                                                                                                                                                                                                                                                                expressed               Unknown                                                                                                                                                                                Oncogene                     \[[@b69-medscimonit-24-8172],[@b71-medscimonit-24-8172]\]
  Intestinal cancer   Unknown                                                                                                                                                                                                                                                                                Overexpressed           GSK3β                                                                                                                                                                                  Oncogene                     \[[@b72-medscimonit-24-8172]\]
  Multiple myeloma    Unknown                                                                                                                                                                                                                                                                                Overexpressed           Paxillin; β-catenin; Src; Akt; STAT3                                                                                                                                                   Oncogene                     \[[@b73-medscimonit-24-8172],[@b77-medscimonit-24-8172]\]
  Ovarian cancer      Phosphorylated Pyk2 is expressed in 82.1% (69/84) of the high-grade serous ovarian cancer                                                                                                                                                                                              Overexpressed           ERK                                                                                                                                                                                    Oncogene                     \[[@b7-medscimonit-24-8172],[@b78-medscimonit-24-8172],[@b79-medscimonit-24-8172]\]
  Prostate cancer     overexpression of Pyk2 is found in 32.4% (26/80) of prostate cancer tissues                                                                                                                                                                                                            expressed               FAK; MAPK; Akt; S6K; ERK                                                                                                                                                               Oncogene/ tumor suppressor   \[[@b81-medscimonit-24-8172],[@b83-medscimonit-24-8172],[@b85-medscimonit-24-8172], [@b87-medscimonit-24-8172],[@b92-medscimonit-24-8172]\]
  Glioma              Astrocytomas (77.4% or 256/331); glioblastomas (84.1% or 169/201); other tumor types of glioma (unknown)                                                                                                                                                                               Overexpressed           Rac1; c-Met; ERK                                                                                                                                                                       Oncogene                     \[[@b94-medscimonit-24-8172],[@b98-medscimonit-24-8172],[@b99-medscimonit-24-8172], [@b101-medscimonit-24-8172],[@b108-medscimonit-24-8172]\]
  SCCHN               Unknown                                                                                                                                                                                                                                                                                Overexpressed           Vimentin; E-cadherin; STAT3                                                                                                                                                            Oncogene                     \[[@b109-medscimonit-24-8172],[@b112-medscimonit-24-8172]\]
  Bladder cancer      Unknown                                                                                                                                                                                                                                                                                Overexpressed           Akt; S6K; ERK                                                                                                                                                                          Oncogene                     \[[@b113-medscimonit-24-8172]\]
  Neuroblastoma       Unknown                                                                                                                                                                                                                                                                                Unknown                 Unknown                                                                                                                                                                                Tumor suppressor             \[[@b115-medscimonit-24-8172]\]
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